The certification has a one-year tail

A marketing application’s clinical data gets the scrutiny — the statistics, the endpoints, the comparison to a predicate. The page that can sink the whole file for a reason that has nothing to do with the device is a one-paragraph certification almost nobody reviews twice: Form FDA 3454, swearing that no investigator on the study had a financial interest big enough to matter.

A form most of a marketing application doesn’t need, until it does

Since February 2, 1999, 21 CFR Part 54 has required a financial-disclosure accounting, for every investigator on a “covered clinical study,” attached to the marketing application built on it. That reaches more than PMAs: a 510(k) resting on a covered clinical study is reached by the same requirement, because the trigger is the study’s role in the application, not the application’s type. A sponsor with nothing disclosable to report files the certification, Form FDA 3454. A sponsor whose investigator crossed a threshold files the disclosure instead, Form FDA 3455, and the application is still reviewed — the rule requires the accounting, not a clean one. What it does not tolerate is an application that omits the accounting altogether: FDA does not review the submission until it is there.

The thresholds the accounting turns on

21 CFR 54.2 sets the line in dollars, not judgment calls. An investigator’s equity interest in the sponsor exceeding $50,000 is disclosable if the sponsor is publicly traded — and if it is not, any equity interest at all is, because there is no public price to measure it against. Significant payments of other sorts — consulting fees, grants beyond the cost of running the study, equity in some other entity tied to the product — are disclosable past $25,000. A proprietary interest in the device itself, a patent or royalty position, is disclosable at any amount. None of that is new to anyone who has built a 3454 before.

What is easy to miss is where the clock actually sits

Each of those thresholds is measured, by the regulation’s own words, during the time the investigator carried out the study and for one year following completion of the study. A sponsor’s instinct is to check financial interests once, at the point the database locks, and carry that answer straight into the certification. The regulation does not stop counting there. An investigator who signs a consulting agreement, or picks up equity, the month after the last subject’s last visit is still inside the window the certification has to speak for — a year past completion, full stop.

A certification signed honestly on the day it was checked can be false on the day it is filed, if nobody checked again before the window it covers actually closed.

The practice

Checking financial interests once, at closeout, and filing that answer months later treats a moving window as a fixed one. The steadier practice is to re-run the financial-interest check immediately before filing, and again before the one-year window closes if it is still open when the application goes in — not to assume the closeout snapshot still holds. These disclosures never become part of the public record FDA releases alongside a clearance or approval; a sponsor cannot check a competitor’s for errors, and nothing in the public file would show if one existed. Clinical-investigator financial disclosure sits outside the four sources this product ingests — Federal Register notices, warning letters, device recalls, and 510(k) clearances, listed on what we monitor and what we deliberately don’t — because it is never part of the public record those sources draw from. Whether a specific investigator’s arrangement crosses Part 54’s line is a determination for the regulatory professional assembling that submission; this is a description of how the window is defined, never a review of any filing’s accuracy.